Abstract:Background: Tumor progression and limited benefits of immune checkpoint blockade (ICB) therapy have been two major challenges in the clinical management of colorectal cancer (CRC). The objective of our research was to explore the role of PLCG2 in CRC progression, tumor microenvironment, and potentiating ICB therapy. Methods: Based on bioinformatics analysis and a prospective clinical observational study, the expression, prognostic significance, and clinical relevance of PLCG2 in CRC were unveiled. The single-cell and spatial transcriptome revealed the role of PLCG2 in shaping the heterogeneity of the CRC tumor microenvironment. The biological function of PLCG2 was validated by in vivo and in vitro experiments. The underlying mechanisms were elucidated by RNA-seq, western blotting, qRT-PCR, and multicolor immunofluorescence. The multiplex immunohistochemistry and flow cytometry were adopted to clarify the immunomodulatory role of PLCG2 in facilitating CRC immune escape. The translational value of targeting PLCG2 to potentiate the efficacy of ICB therapy and synergistic therapy to improve prognosis was explored in the preclinical animal models. Results: In CRC, PLCG2 exhibited high expression levels and was strongly associated with poor prognosis and advanced clinicopathological characteristics of patients. The single-cell transcriptome shed light on its important role in cell communication and the development and differentiation of immune cells. The spatial transcriptome described the spatial distribution of PLCG2 in CRC tissues. Further mechanistic analysis demonstrated that PLCG2 could promote proliferation, invasion, metastasis, epithelial-mesenchymal transition, and cell cycle regulation and inhibit apoptosis of CRC cells via the Akt-mTOR pathway activation. Furthermore, PLCG2 was found to contribute greatly to the immunosuppressive microenvironment and enhanced immune escape as it significantly suppressed the infiltration and functional activation of CD8+ T cells and promoted the infiltration of Treg cells as well as PD-1 and PD-L1 expression. Meanwhile, knockdown of PLCG2 could potentiate the efficacy of ICB therapy. Conclusion: In summary, we have identified for the first time that PLCG2 could be considered a precise biomarker and promising therapeutic target for predicting CRC prognosis, optimizing individualized treatment, reversing CRC immune escape, and overcoming resistance to ICB therapy.

CBLC promotes the development of colorectal cancer by promoting ABI1 degradation to activate the ERK signaling pathway

CBLN2 Overexpression Inhibits Colorectal Cancer Progression and Improves Immunotherapy Responses

ABLIM1, a novel ubiquitin E3 ligase, promotes growth and metastasis of colorectal cancer through targeting IĸBα ubiquitination and activating NF-ĸB signaling

Identification of Molecular Patterns of Anoikis and Epithelial-Mesenchymal Transition-Combined Index for Colorectal Cancer and the Regulatory Role of LTBP1 in Colorectal Cancer

Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.

Upregulation of CPE promotes cell proliferation and tumorigenicity in colorectal cancer

KLHL21/CYLD signaling confers aggressiveness in bladder cancer through inactivating NF-κB signaling

Bcl-3 Promotes Wnt Signaling by Maintaining the Acetylation of Β-Catenin at Lysine 49 in Colorectal Cancer

CBLL1 is Highly Expressed in Non‐small Cell Lung Cancer and Promotes Cell Proliferation and Invasion

Comprehensive Analysis Reveals KLB As a Prognostic Biomarker in Colorectal Cancer Based on Systematic Pancancer Analysis

UBQLN4 is Activated by C/EBPβ and Exerts Oncogenic Effects on Colorectal Cancer Via the Wnt/β-catenin Signaling Pathway

Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression

A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression

CREB1 Contributes Colorectal Cancer Cell Plasticity by Regulating Lncrna CCAT1 and NF-κB Pathways

PICALM exerts a role in promoting CRC progression through ERK/MAPK signaling pathway

LACTB Regulates PIK3R3 to Promote Autophagy and Inhibit EMT and Proliferation Through the PI3K/AKT/mTOR Signaling Pathway in Colorectal Cancer

Stabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma

Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer.

LINC00265 Promotes Colorectal Tumorigenesis Via ZMIZ2 and USP7-mediated Stabilization of Β-Catenin

E3 Ligase C-Cbl Mediates Ubiquitination-Proteasomal Degradation Of Bcr-Abl And Therapeutic Effects Against Bcr-Abl Leukemia

CDC42EP3 promotes colorectal cancer through regulating cell proliferation, cell apoptosis and cell migration